Clinical Trials

AIR: Randomized, double-blind, multicenter, placebo-controlled pivotal trial1,4

Patients were either New York Heart Association (NYHA) Functional Class III or IV and were treated with 2.5 or 5.0 mcg of iloprost 6 to 9 times per day.

The combined primary endpoint was clinical response at 12 weeks, defined as:

  1. At least 10% increase vs baseline in 6-minute walk distance1,4
  2. Improvement by at least one NYHA Functional Class vs baseline1,4
  3. Lack of clinical deterioration or death1,4

STEP: Randomized, double-blind, placebo-controlled phase 2 trial15